Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last?

Revista Espanola de Enfermedades Digestivas

Volumn 101, Issue 8, 2009, Pages 553-564

  Bixquert Jiménez, Miguel ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

Author keywords

Functional digestive disorders; Intestinal microflora; Irritable bowel syndrome (IBS); Mucosal associated microbiota (MAM)

Indexed keywords

ANALGESIC AGENT; ANTACID AGENT; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; HYPNOTIC SEDATIVE AGENT; LAXATIVE; NON PRESCRIPTION DRUG; PLACEBO; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; SPASMOLYTIC AGENT;

ABDOMINAL PAIN; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIUM ISOLATION; BACTEROIDES FRAGILIS; BIFIDOBACTERIUM; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM LONGUM INFANTIS; CLINICAL TRIAL; CLOSTRIDIA; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM PERFRINGENS; COLON FLORA; DEFECATION HABIT; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ESCHERICHIA COLI; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOMODULATION; INFECTIOUS DIARRHEA; INTESTINE FLORA; INTESTINE MOTILITY; INTESTINE MUCOSA; IRRITABLE COLON; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; NONHUMAN; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW; SACCHAROMYCES BOULARDII; STREPTOCOCCUS; TRAVELLER DIARRHEA; VEILLONELLA;

EID: 74849116063     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082009000800006     Document Type: Review

References (76)

1. Longstreth GF, Thomson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
2. Lehrer JK, Lichtenstein GR. Irritable bowel syndrome. On line: eMedicine Specialties / Gastroenterology / Colon. Updated: Sep. 9, 2008.
3. Faresjö A, Grodzinsky E, Johansson S, Wallander MA, Faresjo T, Timpka T. Self-reported use of pharmaceuticals among patients with irritable bowel syndrome in primary care. J Manag Care Pharm 2008; 14: 870-7.
4. Gilkin RJ. The spectrum of irritable bowel syndrome: a clinical review. Clin Therap 2005; 27: 1696-709.
5. Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut 2004; 53: 666-72.
6. Agrawal A, Whorwell PJ. Abdominal bloating and distension in functional gastrointestinal disorders - epidemiology and exploration of possible mechanisms. Aliment Pharmacol Ther 2008; 27: 2-10.
7. Hamaguchi T, Fukudo S, Kanazawa M, Tomiie T, Shimizu K, Oyama M, et al. Changes in salivary physiological stress markers induced by muscle stretching in patients with irritable bowel syndrome. Biopsychosoc Med 2008; 2: 20.
8. Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001; 121: 799-804.
9. Camilleri M, Atanasova E, Carlson PJ, Ahmad U, Kim HJ, Viramontes BE, et al. Serotonin transporter polymorphism pharmacogenetics in diarrea-predominant irritable bowel syndrome. Gastroenterology 2002; 123: 425-32.
10. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001; 48: 14-9.
11. Verdu E, Collins SM. Microbial-gut interactions in health and disease. Irritable bowel syndrome. Best Pract Res Clin Gastroenterol 2004; 18: 315-21.
12. Talley NJ. Irritable bowel syndrome. Intern Med J 2006; 36: 724-8.
13. Liebregts T, Adam B, Bredack C, Röth A, Heinzel S, Lester S, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-20.
14. Zhang H, Yan Y, Shi R, Lin Z, Wang M, Lin L. Correlation of gut hormones with irritable bowel syndrome. Digestion 2008; 78: 72-6.
15. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-83.
16. Mayer EA, Berman S, Suyenobu B, Labus J, Mandelkern MA, Naliboff BD, et al. Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain 2005; 115: 398-409.
17. Morgan V, Pickens D, Gautam S, Kessler R, Mertz H. Amitryptiline reduces rectal pain related activation of the anterior cingulated cortex in patients with irritable bowel syndrome. Gut 2005; 54: 601-7.
18. McNally MA, Locke GR, Zinsmeister AR, Schleck CD, Peterson J, Talley NJ. Biliary events and an increased risk of new onset irritable bowel syndrome: a population-based cohort study. Aliment Pharmacol Ther 2008; 28: 334-43.
19. Lim B, Manheimer E, Lao L, Ziea E,Wisniewski J, Liu J, Berman B. Acupuncture for treatment of irritable bowel síndrome. Cochrane Database Syst Rev 2006; 4: CD005111.
20. Harris LA, Hansel S, DiBaise J, Crowell MD. Irritable bowel syndrome and chronic constipation: emerging drugs, devices, and surgical treatments. Curr Gastroenterol Rep 2006; 8: 282-90.
21. Hussain Z, Quigley EMM. Systematic review: complementary and alternative medicine in the irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 465-71.
22. Jarcho JM, Chang L, Berman M, Suyenobu B, Naliboff BD, Lieberman MD, et al. Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study. Aliment Pharmacol Ther 2008; 28: 344-52.
23. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: 1388-92.
24. Jones R. Treatment of irritable bowel syndrome in primary care. Ispaghula, antispasmodics, and peppermint oil should be considered. BMJ 2008; 337: 1361-2.
25. Fayyaz M, Lackner JM. Serotonin receptor modulators in the treatment of irritable bowel syndrome. Ther Clin Risk Man 2008; 4: 41-8.
26. Quigley EAA. Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management. J Dig Dis 2007; 8: 2-7.
27. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33.
28. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352: 1187-9.
29. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 1231-8.
30. Talley NJ. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol Motil 2008; 20(Supl. 1): 121-9.
31. Salminen S, Isolauri E, Salminen E. Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges. Antonie Van Leeuwenhoek 1996; 70: 347-58.
32. a ed. Madrid: Editorial Panamericana; 2007. p. 183-95.
33. Bharucha AE. Lower gastrointestinal functions. Neurogastroenterol Motil 2008; 20(Supl. 1): 103-13.
34. Lee HR, Pimentel M. Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth. Curr Gastroenterol Rep 2006; 8: 305-11.
35. Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simren M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007; 56: 802-8.
36. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102: 2047-56.
37. Strauch UG, Obermeier F, Grunwald N, Gürster S, Dunger N, Schultz M, et al. Influence of intestinal bacteria on induction of regulatory T cells: lessons from a transfer model of colitis. Gut 2005; 54: 1546-52.
38. Guarner F, Khan AG, Garisch J, Eliakim R, et al. Guías prácticas de la OMGE. Probióticos y prebióticos. Mayo 2008. Disponible en: http://www.worldgastroenterology.org/assets/downloads/es/pdf/ guidelines/19-probioticos-prebioticos-es.pdf.
39. Vargas F. Desayuno de trabajo: Probióticos en Gastroenterología. Congreso Mexicano de Gastroenterología, Veracruz, México, 18 de noviembre 2008. Comunicación personal.
40. Grupo de trabajo. Manejo del paciente con síndrome del intestino irritable. Guía de práctica clínica no 5. Barcelona: AEG, SemFYC y Centro Cochrane Iberoamericano; 2005.
41. Sullivan A, Nord CE. Probiotics and gastrointestinal diseases. J Intern Med 2005; 257: 78-92.
42. Young P, Cash BD. Probiotic use in irritable bowel syndrome. Curr Gastroenterol Rep 2006; 8: 321-6.
43. NASPGHAN Nutrition Report Committee, Michail S, Sylvester F, Fuchs G, Issenman R. Clinical practice guideline. Clinical efficacy of probiotics: review of the evidence with focus on children. J Pediatr Gastroenterol Nutr 2006; 43: 550-7.
44. Borowiec AM, Fedorak RN. The role of probiotics in management of irritable bowel syndrome. Curr Gastroenterol Rep 2007; 9: 393-400.
45. Quigley EAA. Probiotics in the management of colonic disorders. Curr Gastroenterol Rep 2007; 9: 434-40.
46. Quigley EAA. Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management. J Dig Dis 2007; 8: 2-7.
47. Quigley EAA, Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and assessment of the evidence to date. Neurogastroenterol Motil 2007; 19: 166-72.
48. Quigley EAA. Probiotics in functional gastrointestinal disorders: what are the facts. Curr Op Pharmacol 2008; 8: 704-8.
49. Camilleri M. Is there a role for probiotics in irritable bowel syndrome? Dig Liv Dis 2006; 38(Supl. 2): S266-S269.
50. Camilleri M. Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol 2006; 40: 264-9.
51. Spiller R. Review article: probiotics and prebiotics in inrritable bowel syndrome. Aliment Pharmacol Ther 2008; 28: 385-6.
52. Maukonen J, Mättö J, Suiko ML, Saarela M. Intra-individual diversity and similarity of salivary and faecal microbiota. J Med Microbiol 2008; 57: 1560-8.
53. Johansson ML, Molin G, Jeppsson B, Nobaek S, et al. Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. Appl Environm Microb 1993; 59: 15-20.
54. Jacobsen CN, Rosenfeldt Nielsen V, Hayford AE, Møller PL, Michaelsen KF, Paerregaard A, et al. Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Appl Environ Microbiol 1999; 65(11): 4949-56.
55. Vanderhoof JA. Probiotics: future directions. Am J Clin Nutr 2001; 73(Supl.): 1152S-1155S.
56. Niedzelin K, Kordecki H, Kosik R. New possibility in the treatment of irritable bowel syndrome: probiotics as a modification of the microflora of the colon. Gastroenterology 1998; 114: A402.
57. Niedzelin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13: 1143-7.
58. Hauschildt E. Lactobacillus plantarum 299v reduces irritable bowel bloating. Am J Clin Nutr 2001; 73: 380S-385S.
59. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002; 47: 2615-20.
60. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomized double-blind placebo-controlled crossover study. Digest Liver Dis 2000; 32: 294-301.
61. Sinn DH, Song JH, Kim HJ, Lee JH, Son HJ, Chang DK, et al. Therapeutic effect of Lactobacillus acidophilus SDC 2012,2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008; 53: 2714-8.
62. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007; 26: 475-86.
63. Agrawal A, Houghton LA, Morris J, Reilly B, Guyonnet D, Goupil Feuillerat N, et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008; 29: 104-14.
64. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581-90.
65. Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol 2004; 38: S104-S106.
66. Kajander K, Myllyluoma E, Rajilić-Stojanović M, Kyrönpalo S, Rasmussen M, Järvenpää S, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008; 27: 48-57.
67. Kim HJ, Camilleri M, McKinzie S, Lempke MB, et al. A randomized controlled trial of a probiotic,, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 895-904.
68. Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17: 687-96.
69. Simren M, Lindh A, Sammelsson L, Olsson J, Posserud I, Strid H, et al. Effect of a yoghurt containing three probiotic bacteria in patients with irritable bowel syndrome (IBS) - A randomized, double-blind, controlled trial. Gastroenterology 2007; 132(Supl. 2): A210.
70. Mcfarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008; 14: 2650-61.
71. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein A, Brandt L, et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut 2008; ePub ahead of print: doi:10.1136/gut.2008.167270.
72. Wolf BW, Garleb KA, Ataya DG, Casas IA. Safety and tolerance of Lactobacillus reuterii in healthy adult male subjects. Microbial ecology in health and disease 1995; 8: 41-50.
73. Salminen MK, Tynkkynen S, Rautelin H, Saxelin M, Vaara M, Ruutu P, et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002; 35(10): 1155-60.
74. Salminen MK, Tynkkynen S, Rautelin H, Poussa T, et al. The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV patients on retroviral therapy: a randomized, placebo-controlled, crossover study. HIV Clin Trials 2004; 5: 183-91.
75. Salminen MK, Rautelin H, Tynkkynen S, Poussa T, Saxelin M, Valtonen V, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L rhamnosus GG. Clin Infect Dis 2004; 38: 62-9.
76. Salminen MK, Rautelin H, Tynkkynen S, Poussa T, Saxelin M, Valtonen V, et al. Lactobacillus bacteremia, species identification, and antimicrobial susceptibility of 85 blood isolates. Clin Infect Dis 2006; 42: e35-44.